Medicinal Genomics is pioneering the genomics of medical cannabis and hemp. In 2011, Medicinal Genomics made worldwide headlines for being the first group to decode the Cannabis Genome. An increasing amount of scientific evidence supports the theory that cannabinoid compounds may have numerous medical benefits. Medicinal Genomics has the largestDNA sequence database of the cannabis plant and is well-positioned to design fingerprinting assays for strain genotyping and sequencing services for strain development. In 2011, Medicinal Genomics was acquired by Courtagen Life Sciences, Inc.

Biotechnology

Cannabis

Health Care

Medicinal Genomics

Brendan M.

Stephen McLaughlin

Stephen Dailey

Nicholas Lawson

Nathan Houde

Yvonne Helbert

Randi Tarricone

Liam K.

Juliana Sillva

Timothy Olcott

Sherman Hom

Rich Upton

Douglas K.

David Rapisarda

Daniel Walsh

Benjamin Amirault

The Scientific Team at Medicinal Genomics is responsible for advancing the understanding of the cannabis genome. This involves conducting research and development on cannabinoid compounds, creating fingerprinting assays for strain genotyping, and providing sequencing services for strain development. Team members collaborate to maintain and expand the largest DNA sequence database of the cannabis plant, leveraging their expertise in bioinformatics and genomics to drive innovation in medical cannabis research.

Scientific Team

Sales and Customer Support

Leadership Team

Scientific Team

About

Team members

Other teams at Medicinal Genomics

Sales and Customer Support

Leadership Team